Literature DB >> 21267004

Type B mandibuloacral dysplasia with congenital myopathy due to homozygous ZMPSTE24 missense mutation.

Rabah Ben Yaou1, Claire Navarro, Susana Quijano-Roy, Anne T Bertrand, Catherine Massart, Annachiara De Sandre-Giovannoli, Juan Cadiñanos, Kamel Mamchaoui, Gillian Butler-Browne, Brigitte Estournet, Pascale Richard, Annie Barois, Nicolas Lévy, Gisèle Bonne.   

Abstract

Mutation in ZMPSTE24 gene, encoding a major metalloprotease, leads to defective prelamin A processing and causes type B mandibuloacral dysplasia, as well as the lethal neonatal restrictive dermopathy syndrome. Phenotype severity is correlated with the residual enzyme activity of ZMPSTE24 and accumulation of prelamin A. We had previously demonstrated that a complete loss of function in ZMPSTE24 was lethal in the neonatal period, whereas compound heterozygous mutations including one PTC and one missense mutation were associated with type B mandibuloacral dysplasia. In this study, we report a 30-year longitudinal clinical survey of a patient harboring a novel severe and complex phenotype, combining an early-onset progeroid syndrome and a congenital myopathy with fiber-type disproportion. A unique homozygous missense ZMPSTE24 mutation (c.281T>C, p.Leu94Pro) was identified and predicted to produce two possible ZMPSTE24 conformations, leading to a partial loss of function. Western blot analysis revealed a major reduction of ZMPSTE24, together with the presence of unprocessed prelamin A and decreased levels of lamin A, in the patient's primary skin fibroblasts. These cells exhibited significant reductions in lifespan associated with major abnormalities of the nuclear shape and structure. This is the first report of MAD presenting with confirmed myopathic abnormalities associated with ZMPSTE24 defects, extending the clinical spectrum of ZMPSTE24 gene mutations. Moreover, our results suggest that defective prelamin A processing affects muscle regeneration and development, thus providing new insights into the disease mechanism of prelamin A-defective associated syndromes in general.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21267004      PMCID: PMC3110044          DOI: 10.1038/ejhg.2010.256

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  42 in total

1.  Subcellular localization and partial purification of prelamin A endoprotease: an enzyme which catalyzes the conversion of farnesylated prelamin A to mature lamin A.

Authors:  F Kilic; D A Johnson; M Sinensky
Journal:  FEBS Lett       Date:  1999-04-30       Impact factor: 4.124

2.  Nucleoplasmic localization of prelamin A: implications for prenylation-dependent lamin A assembly into the nuclear lamina.

Authors:  R J Lutz; M A Trujillo; K S Denham; L Wenger; M Sinensky
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-01       Impact factor: 11.205

3.  Compound heterozygous ZMPSTE24 mutations reduce prelamin A processing and result in a severe progeroid phenotype.

Authors:  S Shackleton; D T Smallwood; P Clayton; L C Wilson; A K Agarwal; A Garg; R C Trembath
Journal:  J Med Genet       Date:  2005-06       Impact factor: 6.318

4.  Restrictive dermopathy: a newly recognized autosomal recessive skin dysplasia.

Authors:  D R Witt; M R Hayden; K A Holbrook; B A Dale; V J Baldwin; G P Taylor
Journal:  Am J Med Genet       Date:  1986-08

5.  Loss of ZMPSTE24 (FACE-1) causes autosomal recessive restrictive dermopathy and accumulation of Lamin A precursors.

Authors:  Claire L Navarro; Juan Cadiñanos; Annachiara De Sandre-Giovannoli; Rafaëlle Bernard; Sébastien Courrier; Irène Boccaccio; Amandine Boyer; Wim J Kleijer; Anja Wagner; Fabienne Giuliano; Frits A Beemer; Jose M Freije; Pierre Cau; Raoul C M Hennekam; Carlos López-Otín; Catherine Badens; Nicolas Lévy
Journal:  Hum Mol Genet       Date:  2005-04-20       Impact factor: 6.150

6.  Replicative potential and telomere length in human skeletal muscle: implications for satellite cell-mediated gene therapy.

Authors:  S Decary; V Mouly; C B Hamida; A Sautet; J P Barbet; G S Butler-Browne
Journal:  Hum Gene Ther       Date:  1997-08-10       Impact factor: 5.695

7.  Heterozygosity for Lmna deficiency eliminates the progeria-like phenotypes in Zmpste24-deficient mice.

Authors:  Loren G Fong; Jennifer K Ng; Margarita Meta; Nathan Coté; Shao H Yang; Colin L Stewart; Terry Sullivan; Andrew Burghardt; Sharmila Majumdar; Karen Reue; Martin O Bergo; Stephen G Young
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-17       Impact factor: 11.205

8.  p.S143F mutation in lamin A/C: a new phenotype combining myopathy and progeria.

Authors:  Janbernd Kirschner; Thomas Brune; Manfred Wehnert; Jonas Denecke; Christina Wasner; Anja Feuer; Thorsten Marquardt; Uwe-Peter Ketelsen; Peter Wieacker; Carsten G Bönnemann; Rudolf Korinthenberg
Journal:  Ann Neurol       Date:  2005-01       Impact factor: 10.422

9.  Prelamin A endoproteolytic processing in vitro by recombinant Zmpste24.

Authors:  Douglas P Corrigan; Danuta Kuszczak; Antonio E Rusinol; Douglas P Thewke; Christine A Hrycyna; Susan Michaelis; Michael S Sinensky
Journal:  Biochem J       Date:  2005-04-01       Impact factor: 3.857

10.  The processing pathway of prelamin A.

Authors:  M Sinensky; K Fantle; M Trujillo; T McLain; A Kupfer; M Dalton
Journal:  J Cell Sci       Date:  1994-01       Impact factor: 5.285

View more
  18 in total

Review 1.  Inner nuclear membrane proteins: impact on human disease.

Authors:  Iván Méndez-López; Howard J Worman
Journal:  Chromosoma       Date:  2012-02-04       Impact factor: 4.316

2.  Human ZMPSTE24 disease mutations: residual proteolytic activity correlates with disease severity.

Authors:  Jemima Barrowman; Patricia A Wiley; Sarah E Hudon-Miller; Christine A Hrycyna; Susan Michaelis
Journal:  Hum Mol Genet       Date:  2012-06-19       Impact factor: 6.150

3.  New ZMPSTE24 (FACE1) mutations in patients affected with restrictive dermopathy or related progeroid syndromes and mutation update.

Authors:  Claire Laure Navarro; Vera Esteves-Vieira; Sébastien Courrier; Amandine Boyer; Thuy Duong Nguyen; Le Thi Thanh Huong; Peter Meinke; Winnie Schröder; Valérie Cormier-Daire; Yves Sznajer; David J Amor; Kristina Lagerstedt; Martine Biervliet; Peter C van den Akker; Pierre Cau; Patrice Roll; Nicolas Lévy; Catherine Badens; Manfred Wehnert; Annachiara De Sandre-Giovannoli
Journal:  Eur J Hum Genet       Date:  2013-10-30       Impact factor: 4.246

4.  Phenotypic heterogeneity of ZMPSTE24 deficiency.

Authors:  Thomas A Cassini; Amy K Robertson; Anna G Bican; Joy D Cogan; Vickie L Hannig; John H Newman; Rizwan Hamid; John A Phillips
Journal:  Am J Med Genet A       Date:  2018-01-17       Impact factor: 2.802

5.  Hallermann-Streiff Syndrome: No Evidence for a Link to Laminopathies.

Authors:  F Kortüm; M Chyrek; S Fuchs; B Albrecht; G Gillessen-Kaesbach; U Mütze; E Seemanova; S Tinschert; D Wieczorek; G Rosenberger; K Kutsche
Journal:  Mol Syndromol       Date:  2011-11-12

Review 6.  Mutations Involved in Premature-Ageing Syndromes.

Authors:  Fabio Coppedè
Journal:  Appl Clin Genet       Date:  2021-06-02

7.  Requirements for efficient proteolytic cleavage of prelamin A by ZMPSTE24.

Authors:  Jemima Barrowman; Corinne Hamblet; Megan S Kane; Susan Michaelis
Journal:  PLoS One       Date:  2012-02-15       Impact factor: 3.240

8.  Antisense-Based Progerin Downregulation in HGPS-Like Patients' Cells.

Authors:  Karim Harhouri; Claire Navarro; Camille Baquerre; Nathalie Da Silva; Catherine Bartoli; Frank Casey; Guedenon Koffi Mawuse; Yassamine Doubaj; Nicolas Lévy; Annachiara De Sandre-Giovannoli
Journal:  Cells       Date:  2016-07-11       Impact factor: 6.600

Review 9.  Lamins and bone disorders: current understanding and perspectives.

Authors:  Chiara Gargiuli; Elisa Schena; Elisabetta Mattioli; Marta Columbaro; Maria Rosaria D'Apice; Giuseppe Novelli; Tiziana Greggi; Giovanna Lattanzi
Journal:  Oncotarget       Date:  2018-04-27

Review 10.  Lipodystrophic laminopathies: Diagnostic clues.

Authors:  Cristina Guillín-Amarelle; Antía Fernández-Pombo; Sofía Sánchez-Iglesias; David Araújo-Vilar
Journal:  Nucleus       Date:  2018-01-01       Impact factor: 4.197

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.